Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Alphamab Oncology ( (HK:9966) ) is now available.
Alphamab Oncology has announced a supplemental agreement regarding a connected transaction with Suzhou Alphamab for technology development. The agreement outlines a payment structure where Jiangsu Alphamab will make an upfront payment followed by milestone payments linked to specific project deliverables. This collaboration is expected to enhance Alphamab’s capabilities in process development and validation, potentially strengthening its position in the oncology sector.
More about Alphamab Oncology
Alphamab Oncology is a biotechnology company focused on the development of innovative oncology therapies. The company operates in the pharmaceutical industry, primarily engaging in the research and development of cancer treatment drugs.
Average Trading Volume: 4,238,972
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.77B
See more insights into 9966 stock on TipRanks’ Stock Analysis page.